Vaccines & Seasonal Guidance: Medical Groups Issue Independent Recommendations for the 2026–2027 Respiratory Virus Season
As the 2026–2027 respiratory virus season approaches, several major U.S. medical organizations have released their own evidence-based recommendations for influenza, COVID-19 and respiratory syncytial virus (RSV) vaccination.
The development comes amid a period in which the U.S. Centers for Disease Control and Prevention (CDC) has not issued a new comprehensive set of recommendations for the 2026–2027 season. Instead, the CDC says its existing influenza recommendations remain in effect while the situation surrounding federal vaccine guidance is being clarified.
Four major medical organizations the American Academy of Family Physicians (AAFP), American Academy of Pediatrics (AAP), American College of Obstetricians and Gynecologists (ACOG), and Infectious Diseases Society of America (IDSA)—have therefore provided guidance for the populations they serve. Their recommendations were developed through evidence review and are focused on protecting people against influenza, COVID-19 and RSV.
What is different about the 2026–2027 season?
The recommendations are notable because they were issued independently by professional medical organizations rather than waiting for a new overarching CDC recommendation.
The groups have divided their guidance according to different populations:
This approach means that vaccine advice can be tailored to a person’s age, pregnancy status, immune status and individual risk factors.
Influenza vaccination remains a major focus
For the 2026–2027 influenza season, the AAP recommends annual influenza vaccination for children 6 months and older, provided there is no medical contraindication. Any licensed influenza vaccine appropriate for the child’s age and health status can be used.
The CDC’s current influenza guidance similarly recommends annual vaccination for people aged 6 months and older. It also identifies young children, older adults, pregnant women, people with certain chronic illnesses and immunocompromised individuals among those at increased risk of complications.
The 2026–2027 U.S. influenza vaccines have also been updated. The FDA recommended changes to all three components of the seasonal vaccines, including an updated influenza A(H3N2) component following the virus’s circulation during the previous season.
What does the guidance say about COVID-19 vaccines?
The AAFP’s 2026–2027 guidance recommends an updated COVID-19 vaccine for adults aged 19 years and older. It recommends two doses of the updated COVID-19 vaccine during the season for adults aged 65 and older, with the second dose six months after the first.
For people with compromised immune systems, IDSA recommends an age-appropriate 2026–2027 COVID-19 vaccine. The organization notes that immunocompromised people can have a higher risk of severe respiratory infections and may have a weaker immune response to vaccination.
The AAP has also issued its own pediatric COVID-19 guidance for the new season, including vaccination recommendations for younger children and children at increased risk.
RSV vaccination also remains important
Respiratory syncytial virus can cause serious illness, particularly in infants, older adults and people with certain underlying conditions.
The AAFP’s guidance recommends an RSV vaccine for adults 75 years and older, as well as adults aged 50–74 years who have increased risk.
IDSA recommends RSV vaccination for adults and adolescents with compromised immunity, with decisions for some groups guided by individual circumstances and discussions with healthcare professionals.
Vaccines can sometimes be given together
Another important point in the 2026–2027 guidance is that eligible people do not necessarily have to make separate appointments for every respiratory vaccine.
AAFP states that influenza, COVID-19 and RSV vaccines, when indicated, can be administered during the same healthcare visit. IDSA similarly says eligible immunocompromised patients may receive age-appropriate COVID-19, influenza and RSV vaccines together.
A healthcare professional can determine which vaccines are appropriate and whether there are any contraindications or precautions.
Why this matters
Respiratory viruses can circulate at the same time, placing additional pressure on hospitals, clinics and households during respiratory virus season.
The independent recommendations demonstrate that major medical organizations continue to review scientific evidence and issue population-specific vaccine guidance. The AAFP, AAP, ACOG and IDSA say their recommendations are intended to provide evidence-based information for clinicians and patients during the 2026–2027 respiratory virus season.
However, these recommendations are U.S.-specific and should not automatically be interpreted as Nigeria’s national immunization policy. Vaccine availability, schedules and public-health recommendations can differ between countries.
The takeaway
The 2026–2027 respiratory virus season comes with updated guidance from several leading medical organizations, covering influenza, COVID-19 and RSV.
For families, older adults, pregnant women, healthcare workers and people with weakened immune systems, staying informed and discussing vaccination with a qualified healthcare professional can help determine which vaccines are appropriate.
Vaccination decisions should be based on current clinical guidance, age, health status, pregnancy status, previous vaccination history and individual risk factors—not social-media claims or outdated information.
This article is for health education and does not replace individualized medical advice.
Sources
The recommendations discussed above are based primarily on current guidance from the CDC, AAP, AAFP and IDSA for the 2026–2027 season.
Comments